Aa
VIT D PREVENTS MYALGIA and CPK on telbivudine
http://download.journals.elsevierhealth.com/pdfs/journals/0168-8278/PIIS0168827811607071.pdf
VITAMIN D SUPPLEMENT PREVENTS MYALGIA AND ELEVATION
OF CPK IN CHRONIC HEPATITIS B PATIENTS TREATED WITH
TELBIVUDINE
Background: Telbivudine is a nucleoside analog used as first line
therapy in patients with chronic HBV infection in Israel. Myopathy
and neuropathy have been reported in patients who received
telbivudine treatment. Vitamin D has been shown to improve test
of muscle function and impact on muscle fiber composition.
Aim: To examine whether adding vitamin D to telbivudine therapy
could improve adverse events of muscle pain and weakness and
prevent Creatine Kinas (CK) elevation.
Methods: 30 patients with HBeAg negative chronic HBV infection
(treatment group, age 41±13 yrs, BMI 25±4, 56% male; 19 Arabs,
9 Jewish, and 2 of Russian descent) received telbivudine 600 mg
daily plus vitamin D3 (Vitamydine drops (Fischer), 2000 IU/d, were
compared to the historical control group who received telbivudine
600 mg daily without vitamin D for 52 weeks (Historical controls,
GLOBE trial-NCT00057265). Creatine kinas (CK) was assessed by
standard biochemistry at various times during follow up. CK
Normal 7X ULN). Adverse
events were assessed by questionnaire. Myopathy was defined as
persistent unexplained muscle aches, pain, or weakness regardless
of the degree of increases in creatine kinas (CK) levels.
Results: All patients were with genotype D, and 56% were male.
Overall, after 1 year of follow up, 76% (23/30) of the treatment
group with vitamin D3 had normal CK, 23% (7/30) had grade 1–2 CK
elevation and none had grade 3–4 CK elevation as compared to 8%
with Grade1–2 CK elevation and 7.5% with Grade 3–4 CK elevation
in the historical controls group. The mean time to CPK elevation
was 40 weeks and ranges between 187–750 U/L. Mean vitamin D
serum level at week 40 was 41±30 (NL > 32 ng/ml). 2% of patients
in the treatment group had muscle pain as compared to 21% in
the historical control group and in a clinical setting (P < 0.001).
Myopathy was absent in the treatment group as compared to 1
patient in the historical controls.
Conclusion: Adding vitamin D to Telbivudine therapy for patients
with chronic HBV genotype D infection may significantly improves
muscle pain and prevent grade 3–4 CK elevation.
VITAMIN D SUPPLEMENT PREVENTS MYALGIA AND ELEVATION
OF CPK IN CHRONIC HEPATITIS B PATIENTS TREATED WITH
TELBIVUDINE
Background: Telbivudine is a nucleoside analog used as first line
therapy in patients with chronic HBV infection in Israel. Myopathy
and neuropathy have been reported in patients who received
telbivudine treatment. Vitamin D has been shown to improve test
of muscle function and impact on muscle fiber composition.
Aim: To examine whether adding vitamin D to telbivudine therapy
could improve adverse events of muscle pain and weakness and
prevent Creatine Kinas (CK) elevation.
Methods: 30 patients with HBeAg negative chronic HBV infection
(treatment group, age 41±13 yrs, BMI 25±4, 56% male; 19 Arabs,
9 Jewish, and 2 of Russian descent) received telbivudine 600 mg
daily plus vitamin D3 (Vitamydine drops (Fischer), 2000 IU/d, were
compared to the historical control group who received telbivudine
600 mg daily without vitamin D for 52 weeks (Historical controls,
GLOBE trial-NCT00057265). Creatine kinas (CK) was assessed by
standard biochemistry at various times during follow up. CK
Normal 7X ULN). Adverse
events were assessed by questionnaire. Myopathy was defined as
persistent unexplained muscle aches, pain, or weakness regardless
of the degree of increases in creatine kinas (CK) levels.
Results: All patients were with genotype D, and 56% were male.
Overall, after 1 year of follow up, 76% (23/30) of the treatment
group with vitamin D3 had normal CK, 23% (7/30) had grade 1–2 CK
elevation and none had grade 3–4 CK elevation as compared to 8%
with Grade1–2 CK elevation and 7.5% with Grade 3–4 CK elevation
in the historical controls group. The mean time to CPK elevation
was 40 weeks and ranges between 187–750 U/L. Mean vitamin D
serum level at week 40 was 41±30 (NL > 32 ng/ml). 2% of patients
in the treatment group had muscle pain as compared to 21% in
the historical control group and in a clinical setting (P < 0.001).
Myopathy was absent in the treatment group as compared to 1
patient in the historical controls.
Conclusion: Adding vitamin D to Telbivudine therapy for patients
with chronic HBV genotype D infection may significantly improves
muscle pain and prevent grade 3–4 CK elevation.
vit d2 is never good because it is not natural but the synthetic patented form of natural vit d, it doesn t even work to increase vit d, it has very weak effect
vit d3 is the natural form of vit d and works best to increase vit d levels, drops have a clear dose just look at instructions with vit d concentration per drop
vit d is absorbed if mixed with oil or a fat meal, dry pills are poorly absorbed
vit d3 is the natural form of vit d and works best to increase vit d levels, drops have a clear dose just look at instructions with vit d concentration per drop
vit d is absorbed if mixed with oil or a fat meal, dry pills are poorly absorbed
Do you think it's better in similar situations, vitimin D3 in the form of drops or vitamin D2 (alfacalcidol with a clear dose)?
our guess was:
since intf+telbivudine has the highest decrease of hbsag by 24 weeks only but myalgia sides why dont they try vit d, well looks like vit d actually works on this too bad they did not try on intf+telbivudine since results of telbivudine monotherapy are non existent plus resistance danger...
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
